乙醇/甲吡唑抑制酒精脱氢酶、不做体外清除治疗乙二醇中毒:系统综述
本系统综述纳入115篇文献中的96篇病例级数据,共180例乙醇单药治疗和231例甲吡唑单药治疗(未行体外清除治疗)的乙二醇中毒患者。治疗失败主要见于治疗前已有明显酸血症和/或急性肾损伤者;乙醇单药治疗在酸血症轻微时也有失败病例,提示乙醇给药和/或监测可能不理想。乙醇单药治疗的失败可由乙二醇剂量和浓度预测,甲吡唑则不能。阴离子间隙分析(207例)显示,阴离子间隙<24 mmol/L时几乎无死亡和急性肾损伤进展,>28 mmol/L时则多见。作者认为,代谢性酸血症轻微(阴离子间隙<28 mmol/L)时单用甲吡唑不做体外清除治疗安全有效,与乙二醇浓度无关。
要点
- 治疗前已有明显酸血症和/或急性肾损伤的乙二醇中毒患者,单用乙醇或甲吡唑(不做体外清除治疗)更易治疗失败。
- 代谢性酸血症轻微(阴离子间隙<28 mmol/L)时,单用甲吡唑而不做体外清除治疗安全有效,与乙二醇浓度无关(作者结论)。
- 阴离子间隙<24 mmol/L的207例分析中,死亡和急性肾损伤进展几乎不存在;阴离子间隙>28 mmol/L时则多见。
- 乙醇单药治疗的失败可由乙二醇剂量和乙二醇浓度预测,甲吡唑单药治疗则不能。
- 乙醇单药治疗即使在酸血症轻微时也有失败病例,提示乙醇给药和/或监测可能不理想。
适用人群与场景
- 已报告的乙二醇中毒患者,接受甲吡唑单药治疗或乙醇单药治疗,未行体外清除治疗(补救性体外清除治疗除外)。
诊断标准与关键阈值
- 治疗失败定义为:死亡、酸碱状态恶化、体外清除治疗作为补救、或启动酒精脱氢酶抑制后肾脏或神经功能恶化。
- 阴离子间隙<24 mmol/L时死亡和急性肾损伤进展几乎不存在;阴离子间隙>28 mmol/L时则多见(阴离子间隙分析207例)。
处置流程与药物剂量
- 竞争性抑制酒精脱氢酶:使用乙醇或甲吡唑,以防止毒性代谢产物形成(原文未给出具体剂量方案)。
- 不做体外清除治疗(如血液透析)的前提是:无显著代谢性酸血症或肾损伤时,使用酒精脱氢酶抑制剂可能免去体外清除治疗而不增加不良结局(原文假设)。
- 代谢性酸血症轻微(阴离子间隙<28 mmol/L)时,单用甲吡唑而不做体外清除治疗安全有效,与乙二醇浓度无关(作者结论)。
红旗征与不能漏的情况
- 治疗前存在明显酸血症和/或急性肾损伤:单药治疗失败主要见于此类患者。
- 乙醇单药治疗即使在酸血症轻微时也有失败病例,可能反映乙醇浓度短暂低于治疗水平或乙二醇浓度极高。
- 阴离子间隙>28 mmol/L:死亡和急性肾损伤进展多见。
研究设计与关键结果
- 系统综述:从115篇文献中识别出96篇含病例级数据;共180例乙醇单药治疗和231例甲吡唑单药治疗。
- 治疗失败主要见于治疗前已有明显酸血症和/或急性肾损伤者;乙醇单药治疗在酸血症轻微时也有失败病例,提示乙醇给药和/或监测可能不理想。
- 乙醇单药治疗的失败可由乙二醇剂量和乙二醇浓度预测,甲吡唑单药治疗则不能。
- 阴离子间隙分析(207例):阴离子间隙<24 mmol/L时死亡和急性肾损伤进展几乎不存在,>28 mmol/L时则多见。
证据类型、等级与局限
- 证据类型:系统综述(纳入病例报告和病例系列)。
- 局限:所纳入病例报告和病例系列的回顾性性质;结果需前瞻性验证(原文自述)。
对床旁实践的改变
- 作者认为:代谢性酸血症轻微(阴离子间隙<28 mmol/L)的乙二醇中毒患者,单用甲吡唑而不做体外清除治疗安全有效,与乙二醇浓度无关。
- 乙醇单药治疗可出现治疗失败,可能与乙醇浓度短暂低于治疗水平或乙二醇浓度极高有关;原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: Ethylene glycol is metabolized to toxic metabolites that cause acute kidney injury, metabolic acidemia, and death. The treatment of patients with ethylene glycol poisoning includes competitively inhibiting alcohol dehydrogenase with ethanol or fomepizole to prevent the formation of toxic metabolites, and extracorporeal treatments such as hemodialysis to remove ethylene glycol and its metabolites. In the absence of significant metabolic acidemia or kidney injury, it is hypothesized that extracorporeal treatments may be obviated without adverse outcomes to the patient if alcohol dehydrogenase inhibitors are used.
OBJECTIVES: The objectives of this study are to: (1) identify indicators predicting ADH inhibitor failure in patients with ethylene glycol poisoning treated with either ethanol or fomepizole for whom extracorporeal treatment was not performed (aside from rescue therapy, see below) (prognostic study), and (2) validate if the anion gap, shown in a previous study to be the best surrogate for the glycolate concentration, is associated with acute kidney injury and mortality (anion gap study).
METHODS: We conducted a systematic review to identify all reported patients with ethylene glycol poisoning treated without extracorporeal treatments but with either fomepizole (fomepizole monotherapy) or ethanol (ethanol monotherapy). Analyses were performed using both one case per patient and all cases (if multiple events were reported for a single patient). Data were compiled regarding poisoning, biochemistry, and outcomes. Treatment failure was defined as mortality, worsening of acid-base status, extracorporeal treatments used as rescue, or a worsening of kidney or neurological function after alcohol dehydrogenase inhibition was initiated. Also, we performed an analysis of previously described anion gap thresholds to determine if they were associated with outcomes such as acute kidney injury and mortality.
RESULTS: Of 115 publications identified, 96 contained case-level data. A total of 180 cases were identified with ethanol monotherapy, and 231 with fomepizole monotherapy. Therapy failure was noted mostly when marked acidemia and/or acute kidney injury were present prior to therapy, although there were cases of failed ethanol monotherapy with minimal acidemia (suggesting that ethanol dosing and/or monitoring may not have been optimal). Ethylene glycol dose and ethylene glycol concentration were predictive of monotherapy failure for ethanol, but not for fomepizole. In the anion gap study (207 cases), death and progression of acute kidney injury were almost nonexistent when the anion gap was less than 24 mmol/L and mostly observed when the anion gap was greater than 28 mmol/L.
CONCLUSION: This review suggests that in patients with minimal metabolic acidemia (anion gap <28 mmol/L), fomepizole monotherapy without extracorporeal treatments is safe and effective regardless of the ethylene glycol concentration. Treatment failures were observed with ethanol monotherapy which may relate to transient subtherapeutic ethanol concentrations or very high ethylene glycol concentrations. The results are limited by the retrospective nature of the case reports and series reviewed in this study and require prospective validation.
参考来源
- Beaulieu J, Roberts DM, Gosselin S, et al. Treating ethylene glycol poisoning with alcohol dehydrogenase inhibition, but without extracorporeal treatments: a systematic review. Clin Toxicol (Phila). 2022. PMID: 35311442. doi:10.1080/15563650.2022.2049810
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。